Biricodar Vertex Pharmaceuticals

Current Opinion in Investigational Drugs

Volumn 3, Issue 5, 2002, Pages 818-823

  Dey, Saibal ^a  

^a Uniformed Services University of the Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AZIDOPINE; BIRICODAR; CYCLOSPORIN A; DOXORUBICIN; ETOPOSIDE; HORMONE; IFOSFAMIDE; MITOXANTRONE; PACLITAXEL; PIPECOLIC ACID DERIVATIVE; PREDNISONE; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINCRISTINE; VX 710 3;

BLOOD TOXICITY; BREAST CANCER; CHEMOSENSITIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TOXICITY; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; METASTASIS; NEUTROPENIA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PIPERIDINES; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036591235     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. 207499 Vertex signs agreement with BioChem to develop and market novel anti-cancer agent in Canada. Vertex Pharmaceuticals Inc Press Release 1996 May 09
2. 212457 Vertex begins phase II clinical trial of multidrug resistance inhibitor, VX-710, in liver cancer. Vertex Pharmaceuticals Inc Press Release 1996 June 27
3. 241024 Vertex and BioCem Pharma advance phase II development of cancer multidrug resistance inhibitor, VX-710, in US and Canada. Vertex Pharmaceuticals Inc Press Release 1997 April 03
4. 274721 Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Germann UA, Ford PJ, Shlakhter D, Mason VS, Harding MW Anti Cancer Drugs 1997 8 2 141-155
5. 289452 Approaches to multidrug resistance reversal. Robert J Expert Opin Investig Drugs 1998 7 6 929-939
6. 292663 Veterx begins clinical trial with Incel to block multidrug resistance in prostate cancer. Vertex Pharmaceuticals Inc Press Release 1998 July 27
7. 299823 Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J, Harding MW Anti Cancer Drugs 1997 8 2 125-140 In vitro demonstration of a direct high affinity interaction of biricodar with P-gp, that prevents P-gp-dependent efflux of cytotoxic drugs.
8. 305297 Vertex begins phase II clinical trial of Incel for treatment of multidrug resistant small cell lung cancer. Vertex Pharmaceuticals Inc Press Release 1998 November 13
9. 306090 Drug development pipeline: Agenerase, VX-710, VX-497, JNK inhibitors, timcodar dimesylate, protease inhibitor Vertex, anti-hepatitis C therapy Vertex. Vertex Pharmaceuticals Inc Company Communication 1998 November 19
10. 309971 Recent strategies for the treatment of multi-drug resistance in cancer cells. Ojima I, Bounaud PY, Oderda CF 1998 8 12 1587-1598
11. 311702 Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M , Drengler R, Stephenson J, Harding MW, Von Hoff DD J Clin Oncol 1998 16 9 2964-2976
12. 327862 A phase II study of the safety, pharmacokinetics and efficacy of INCEL (Biricodar, VX-710) in combination with mitoxantrone and prednisone in advanced hormone refractory prostate cancer. Einstein AB, Marsh MJ, Lush R, Rago R, Ko Y-J, Bubley G, Merica EA, Ette E, Harding MW, Dalton WS Proc Am Soc Clin Oncol 1999 18 May 15-18 Abs 1301
13. 334730 Clinical trials of P-glycoprotein reversal in solid tumours. Ferry DR, Traunecker H, Kerr DJ Eur J Cancer 1996 32A 6 1070-1081
14. 347956 Vertex reports phase II clinical data on Incel for treatment of advanced hormone-refractory prostate cancer. Vertex Pharmaceuticals Inc Press Release 1999 November 18
15. 355339 BIRICODAR (VX-710; Incel): An effective chemosensitizer in neuroblastoma. Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton CR, Pritchard-Jones K Br J Cancer 1999 80 8 1190-1196
16. 358001 Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, Scheper RJ, Borst P, Oude Elferink RP Science 1996 270 5252 1126-1128
17. 358005 A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, Ter Borg F, Scheper RJ, Tytgat GN, Borst P, Baas F, Oude Elferink RP Hepatology 1997 25 6 1539-1542
18. 358009 Hepatic expression of multidrug resistance-associated protein-like proteins maintained in Eisai hyperbilirubinemic rats. Hirohashi T, Suzuki H, Ito K, Ogawa K, Kume K, Shimizu T, Sugiyama Y Mol Pharmacol 1998 53 6 1068-1075
19. 397989 Vertex Pharmaceuticals Inc/MA Form 10-K: BioChem Pharma. Vertex Pharmaceuticals Inc 2000 March 03 16
20. 427362 Pipeline and products. Vertex Pharmaceuticals Inc Company World Wide Web Site 2001 September 24
21. 435605 Pipeline and products. Vertex Pharmaceuticals Inc Company World Wide Web Site 2002 January 08
22. 99 Tc-sestamibi imaging.
23. 447389 Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. Loe DW, Almquist KC, Deeley RG, Cole SP J Biol Chem 1996 271 16 9675-9682
24. 447390 Transport function and substrate specificity of multidrug resistance protein. Keppler D, Keppler D, Jedlitschky G, Leier I Methods Enzymol 1998 292 607-616
25. 447397 Safety and efficacy of the multidrug-resistant inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Bramwell VH, Morris D, Ernst DS, Hings I, Blaclstein M, Venner PM, Ette EI, Harding MW, Waxman A, Demetri GD Clin Cancer Res 2002 8 2 383-393 In the phase II part of this trial, biricodar and doxorubicin resulted in objective responses or diseases stabilizations in patients with anthracycline-refractory non-GIST soft tissue sarcomas.
26. 447401 Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD Clin Cancer Res 2002 8 3 670-678
27. 447405 Chemotherapy for advanced sarcoma: Therapeutic decisions and modalities. Keohan ML, Taub RN Semin Oncol 1997 24 5 572-579
28. 447408 MDRI gene expression: Evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Stein U, Shoemaker RH, Schlag PM Eur J Cancer 1996 32A 1 86-92
29. 447413 Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. Bradshaw DM, Arceci RJ J Clin Oncol 1998 16 11 3674-3690
30. 447415 Biology of the multidrug resistance-associated protein, MRP. Loe DW, Deeley RG, Cole SP Eur J Cancer 1996 32A 6 945-957
31. 447416 The function of the multidrug resistance proteins (MRP and cMRP) in drug conjugate transport and hepatobiliary excretion. Keppler D, Leier I, Jedlitschky G, Mayer R, Buchler M Adv Enzyme Regul 1996 36 17-29
32. 447418 cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. Buchler M, Konig J, Brom M, Kartenbeck J, Spring H, Horie T, Keppler D J Biol Chem 1996 271 25 15091-15098
33. 447421 Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles. Mazzanti R, Fantappie O, Kamimoto Y, Gatmaitan Z, Gentilini P, Arias IM Hepatology 1994 20 1 Pt 1 170-176
34. 447425 Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Kartenbeck J, Leuschner U, Mayer R, Keppler D Hepatology 1996 23 5 1061-1066
35. 447429 P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V N Engl J Med 1991 325 23 1608-1614
36. 447430 Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL Blood 1997 89 9 3323-3329
37. 447434 Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D Blood 1992 79 2 473-476
38. 447436 Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: Prognostic implications. Goasguen JE, Dossot JM, Fardel O, Le Mee F, Le Gall E, Leblay R, LePrise PY, Chaperon J, Fauchet R Blood 1993 81 9 2394-2398
39. 447437 P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Zochbauer S, Gsur A, Brunner R, Kyrle PA, Lechner K, Pirker R Leukemia 1994 8 6 974-977
40. 447439 Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O Blood 1995 85 8 2147-2153
41. 447441 The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Nooter K, Brutel De La Riviere G, Look MP, Van Wingerden KE, Henzen-Logmans SC, Scheper RJ, Flens MJ, Klijn JG, Stoter G, Foekens JA Br J Cancer 1997 76 4 486-493
42. 447446 Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T et al Br J Cancer 1995 72 3 550-554
43. 447447 Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA J Natl Cancer Inst 1999 91 5 429-433
44. 447450 Circumventon of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Maliepaard M, Van Gastelen MA, Tohgo A, Hausheer FH, Van Waardenburg RC, De Jong LA, Pluim D, Beijnen JH, Schellens JH Clin Cancer Res 2001 7 4 935-941
45. 447452 Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Maliepaard M, Van Gastelen MA, De Jong LA, Pluim D, Van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH Cancer Res 1999 59 18 4559-4563
46. 447840 Immune Design System Applications of structure-aided drug design: Comparative X-ray structures of the major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and rapamycinK. Wilson KP, Yamashita MM, Sintchak MD, Rotstein SH, Murcko MA, Boger J, Thomson JA, Fitzgibbon, Black JR, Navia MA Acta Crystallogr, Section D: Biol Crystallogr 1995 51 4 511-521
47. 447841 A phase II study with the MDR inhibitor Incel™ (Biricodar, VX-710) with paclitaxel in strictly defined paclitaxel refractory ovarian cancer patients. Seiden MV Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow 2000 XVII. Although this phase II study only achieved a partial response in two out of 48 patients with ovarian cancer, 52% of the patients experienced an extended progression-free interval.
48. 449202 Vertex Pharmaceuticals Inc: Coverage iniated with rating of buy and price target of $34: Biopharma boasts industrial-scale drug discovery engine. Reddoch JF, Cutler AD Banc of America 2002 January 03 Basic biotechnology/genomics report, forecasting that biricodar has a 30% chance of reaching the market with a launch date in the second half of 2005 and peak sales estimated at $250 million.
49. 450813 Vertex Pharmaceuticals Inc: Data on file. Vertex Pharmaceuticals Inc Company Communication 2002 May 10 Michele Karpf Belansky, on behalf of several clinical experts at Vertex, updated results of a phase II trial of biricodar in combination with mitoxantrone and prednisone, conducted in patients with prostate cancer. There was a PSA response in 30% of patients, marked by a ≥ 80% drop in PSA sustained for a median duration of 33 weeks.
50. 450814 A phase II study of the MDR inhibitor biricodar and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier C Gynecol Oncol 2002 in press